Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL)
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Ocular |
| Therapuetic Areas: | Ophthalmology |
| Healthy: | No |
| Age Range: | 50 - Any |
| Updated: | 2/1/2017 |
| Start Date: | July 2010 |
| End Date: | December 2017 |
The VITamin D and OmegA-3 Trial (VITAL; NCT 01169259) is a randomized clinical trial in
25,875 U.S. men and women investigating whether taking daily dietary supplements of vitamin
D3 (2000 IU) or omega-3 fatty acids (Omacor fish oil, 1 gram) reduces the risk of developing
cancer, heart disease, and stroke in people who do not have a prior history of these
illnesses. This ancillary study is being conducted among participants in VITAL and will
examine whether vitamin D or omega-3 fatty acids, compared to placebo, reduce the incidence
and/or progression of age-related macular degeneration (AMD).
25,875 U.S. men and women investigating whether taking daily dietary supplements of vitamin
D3 (2000 IU) or omega-3 fatty acids (Omacor fish oil, 1 gram) reduces the risk of developing
cancer, heart disease, and stroke in people who do not have a prior history of these
illnesses. This ancillary study is being conducted among participants in VITAL and will
examine whether vitamin D or omega-3 fatty acids, compared to placebo, reduce the incidence
and/or progression of age-related macular degeneration (AMD).
This ancillary study to the VITamin D and OmegA-3 TriaL (VITAL) will examine whether vitamin
D3 and omega-3 fatty acids can help prevent the onset or progression of age-related macular
degeneration (AMD). The study will also examine whether vitamin D3 and omega-3 fatty acids
interact with each other, or with specific genes associated with AMD or vitamin D3 or
omega-3 fatty acid metabolic activity, to affect the risk of developing AMD.
D3 and omega-3 fatty acids can help prevent the onset or progression of age-related macular
degeneration (AMD). The study will also examine whether vitamin D3 and omega-3 fatty acids
interact with each other, or with specific genes associated with AMD or vitamin D3 or
omega-3 fatty acid metabolic activity, to affect the risk of developing AMD.
Inclusion Criteria:
- All participants in VITAL (NCT 01169259) are eligible to participate in this
ancillary study.
Exclusion Criteria:
We found this trial at
1
site
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
Click here to add this to my saved trials
